DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Sadie Stern sold 2,565 shares of the firm's stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $88.37, for a total value of $226,669.05. Following the completion of the transaction, the executive vice president owned 126,043 shares in the company, valued at $11,138,419.91. This represents a 1.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
DexCom Stock Up 1.7%
Shares of NASDAQ:DXCM opened at $90.82 on Friday. The business's 50 day moving average is $79.21 and its 200 day moving average is $71.60. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $92.59. The stock has a market cap of $34.27 billion, a price-to-earnings ratio of 35.90, a PEG ratio of 1.51 and a beta of 1.41. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47.
DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.61 by $0.09. The business had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.DexCom's quarterly revenue was up 13.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.48 EPS. On average, sell-side analysts forecast that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Reflection Asset Management purchased a new stake in shares of DexCom during the 4th quarter valued at $25,000. Ascentis Independent Advisors purchased a new position in shares of DexCom in the 1st quarter worth about $25,000. MCF Advisors LLC purchased a new position in shares of DexCom in the 4th quarter worth about $32,000. Wellington Grp LLC grew its position in DexCom by 778.7% during the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company's stock valued at $34,000 after buying an additional 475 shares during the period. Finally, DV Equities LLC bought a new position in DexCom during the fourth quarter valued at about $36,000. Institutional investors own 97.75% of the company's stock.
Analysts Set New Price Targets
Several analysts have recently commented on the stock. Robert W. Baird set a $105.00 target price on shares of DexCom in a report on Friday, July 31st. Wall Street Zen cut shares of DexCom from a "buy" rating to a "hold" rating in a report on Saturday. Royal Bank Of Canada upped their price objective on shares of DexCom from $85.00 to $90.00 and gave the stock an "outperform" rating in a research report on Friday, July 31st. Sanford C. Bernstein set a $77.00 price objective on shares of DexCom in a research report on Friday, May 1st. Finally, Canaccord Genuity Group set a $90.00 price objective on shares of DexCom and gave the company a "buy" rating in a research note on Monday, August 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $88.71.
Get Our Latest Stock Report on DexCom
DexCom Company Profile
(
Get Free Report)
DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.
Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
